Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Literature
1.
Harrison C, Kiladjian JJ, Al-Ali HK et al (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366:787–798PubMedCrossRef
2.
Verstovsek S, Mesa RA, Gotlib J et al (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366:799–807PubMedCrossRef
3.
O’Shea JJ, Holland SM, Staudt LM (2013) JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 368:161–170PubMedCrossRef
4.
Kontzias A, Kotlyar A, Laurence A et al (2012) Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. Curr Opin Pharmacol 12:464–470PubMedCentralPubMedCrossRef
5.
Tefferi A (2012) JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood 119:2721–2730PubMedCrossRef
6.
Wathes R, Moule S, Milojkovic D (2013) Progressive multifocal leukoencephalopathy associated with ruxolitinib. N Engl J Med 369:197–198PubMedCrossRef
7.
Goldberg RA, Reichel E, Oshry LJ (2013) Bilateral toxoplasmosis retinitis associated with ruxolitinib. N Engl J Med 369:681–683PubMedCrossRef
Metadata
Title
Hepatitis B virus reactivation associated with ruxolitinib
Authors
Chien-Heng Shen
Cih-En Hwang
Yi-Yang Chen
Chih-Cheng Chen
Publication date
01-06-2014
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 6/2014
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-013-1936-5

Other articles of this Issue 6/2014

Annals of Hematology 6/2014 Go to the issue

Original Article

Prognostic impact of beta-2 microglobulin in patients with extranodal natural killer/T cell lymphoma

Letter to the Editor

Bone marrow aspiration and biopsy-related pain management

Letter to the Editor

Primary myelofibrosis: when the clone manifests with Rh phenotype splitting

Original Article

Hereditary gene mutations in Korean patients with isolated erythrocytosis

Letter to the Editor

Mast cell sarcoma mimicking metastatic colon carcinoma

Original Article

Histone deacetylase inhibitor prevents cell growth in Burkitt’s lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits